Galectin Therapeutics (Galectin Therapeutics) Cash-to-Debt : 0.36 (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Galectin Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Galectin Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.36.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Galectin Therapeutics couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Galectin Therapeutics's Cash-to-Debt or its related term are showing as below:

GALT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.36 Med: 5608.72 Max: No Debt
Current: 0.36

During the past 13 years, Galectin Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.36. And the median was 5608.72.

GALT's Cash-to-Debt is ranked worse than
88.24% of 1539 companies
in the Biotechnology industry
Industry Median: 6.42 vs GALT: 0.36

Galectin Therapeutics Cash-to-Debt Historical Data

The historical data trend for Galectin Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Galectin Therapeutics Cash-to-Debt Chart

Galectin Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

1,217.44

616.86

1.37

0.47

0.36

Galectin Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															0.47	0.36	0.30	0.33	0.36

Competitive Comparison of Galectin Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Galectin Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galectin Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galectin Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Galectin Therapeutics's Cash-to-Debt falls into.

Galectin Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Galectin Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	25.66	/	(0.046	+	71.741)
	=	0.36

Galectin Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	25.66	/	(0.046	+	71.741)
	=	0.36

Galectin Therapeutics (NAS:GALT) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Galectin Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Galectin Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Galectin Therapeutics (Galectin Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galectin Therapeutics Inc (NAS:GALT) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

PHPN:Germany

Address

4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071

Website

https://www.galectintherapeutics.com

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Executives

Kary Eldred	director	2121 RINGWOOD AVENUE, SAN JOSE CA 95131
Kevin D Freeman	director	712 LAKEWAY DRIVE, KELLER TX 76248
Zordani Richard A. Jr.	director	467 N. COUNTRY RIDGE CT., LAKE ZURICH IL 60047
10x Fund, L.p.	10 percent owner	1099 FOREST LAKE TERRACE, NICEVILLE FL 32578
Elissa J. Schwartz	director	235 SW CHURCH ST., PULLMAN WA 99163
Gilbert F Amelio	director	5835 STRASBOURG COURT, ---, RENO NV 89511
Richard E Uihlein	director, 10 percent owner	12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158
Pol F Boudes	officer: Chief Medical Officer	C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Joel Lewis	director	12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158
Gilbert S Omenn	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Harold H. Shlevin	director, officer: Chief Executive Officer	C/O GALECTIN THERAPEUTICS, INC., 4690 PEACHTREE INDUSTRIAL BLVD, STE. 240, NORCROSS GA 30071
Jack W Callicutt	officer: Chief Financial Officer	75 FIFTH STREET NW STE. 313, ATLANTA GA 30308
Marc Rubin	director	C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
James C Czirr	director	4908 SOUTH ASHTON COURT, SPOKANE WA 99223
Peter G Traber	director, officer: President and CEO	430 THAMER LANE, HOUSTON TX 77025